http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Daidzein Activates Choline Acetyltransferase from MC-IXC Cells and Improves Drug-Induced Amnesia
HEO, Ho Jin,SUH, Young-Min,KIM, Mi-Jeong,CHOI, Soo-Jung,MUN, Nam Shik,KIM, Hye-Kyung,KIM, Eunki,KIM, Chang-Ju,CHO, Hong-Yon,KIM, Young Jun,SHIN, Dong-Hoon Japan Society for Bioscience, Biotechnology, and A 2006 Bioscience, Biotechnology, and Biochemistry Vol.70 No.1
<P>The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission <I>via</I> an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer’s disease (AD). Methanolic extracts from <I>Pueraria thunbergiana</I> exhibited an activation effect (46%) on ChAT <I>in vitro</I>. <I>Via</I> the sequential isolation of <I>Pueraria thunbergiana</I>, the active component was ultimately identified as daidzein (4′,7-dihydroxy-isoflavone). In order to investigate the effects of daidzein from <I>Pueraria thunbergiana</I> on scopolamine-induced impairments of learning and memory, we conducted a series of <I>in vivo</I> tests. Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test. Injections of scopolamine into mice resulted in impaired performance on Y-maze tests (a 37% decreases in alternation behavior). By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%–21% decrease in alternation behavior). These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.</P>
Lee, Yedaun,Lee, Seung Soo,Kim, Namkug,Kim, Eunki,Kim, Yeong Jae,Yun, Sung-Cheol,K?hn, Bernd,Kim, In Seong,Park, Seong Ho,Kim, So Yeon,Lee, Moon-Gyu Radiological Society of North America 2015 Radiology Vol.274 No.2
<P>To compare the influence of triggering methods for diffusion-weighted imaging (DWI) on apparent diffusion coefficient (ADC) and intravoxel incoherent motion (IVIM) parameters in the liver, as well as regional variability and measurement repeatability.</P>
( Eunki Chung ),( Dawoon Jeong ),( Jeongha Mok ),( Doosoo Jeon ),( Hee-yeon Kang ),( Heejin Kim ),( Heesun Kim ),( Hongjo Choi ),( Young Ae Kang ) 대한내과학회 2024 The Korean Journal of Internal Medicine Vol.39 No.2
Background/Aims: To determine whether metformin, which is considered a host-directed therapy for tuberculosis (TB), is effective in improving the prognosis of patients with TB and diabetes mellitus (DM), who have higher mortality than those without DM. Methods: This cohort study included patients who were registered as having TB in the National Tuberculosis Surveillance System. The medical and death records of matched patients were obtained from the National Health Information Database and Statistics Korea, respectively, and data from 2011 to 2017 were collected retrospectively. We classified patients according to metformin use among participants who used diabetes drugs for more than 28 days. The primary outcome was all-cause mortality during TB treatment. Double propensity score adjustment was applied to reduce the effects of confounding and multivariable Cox proportional hazard models were used to estimate adjusted hazard ratio (aHR) with 95% confidence interval (CI). Results: The all-cause mortality rate during TB treatment was lower (9.5% vs. 12.4%, p < 0.01) in the metformin user group. The hazard of death due to all causes after double propensity score adjustment was also lower in the metformin user group (aHR 0.76, 95% CI 0.67-0.86, p < 0.01). There was no significant difference in mortality between metformin users and non-users for TB-related deaths (p = 0.22); however, there was a significant difference in the non-TB-related deaths (p < 0.01). Conclusions: Metformin use in patients with TB-DM co-prevalence is associated with reduced all-cause mortality, suggesting the potential for metformin adjuvant therapy in these patients.